| Literature DB >> 35892606 |
Ayla Yagdiran1, Charlotte Meyer-Schwickerath2, Raphael Wolpers1, Christina Otto-Lambertz1, Katrin Mehler3, Andre Oberthür3, Nikolaus Kernich1, Peer Eysel1, Norma Jung2, Kourosh Zarghooni1.
Abstract
Pediatric spondylodiscitis (PSD) is a rare disease with a major impact on mobility and functional status. Data concerning demographic and microbiological characteristics, clinical course, treatment, and outcome are scarce. Therefore, the aim of this study was to present clinical experiences of a third-level hospital (2009-2019) in PSD and compare these with adult spondylodiscitis (ASD). Of a total of 10 PSD patients, most of the infants presented with unspecific pain such as hip pain or a limping, misleading an adequate diagnosis of spine origin. Eight patients could be treated conservatively whereas surgery was performed in two cases with one case of tuberculous PSD (tPSD). The causative agent was detected in three of the patients. The diagnosis of PSD is often difficult since clinical symptoms are unspecific and causative pathogens often remain undetected. Nevertheless, empirical anti-infective therapy also seems to be effective. Based on recent studies, clinicians should be encouraged to keep the duration of anti-infective therapy in children short. Since comorbidities are not presented in PSD it is unclear which children suffer from PSD; thus, studies are necessary to identify predisposing factors for PSD. In our study, PSD differs from ASD in diagnostic and especially in therapeutic aspects. Therefore, specific guidelines for PSD would be desirable.Entities:
Keywords: clinical course; diagnosis; pediatric spondylodiscitis; predicting factors; treatment
Year: 2022 PMID: 35892606 PMCID: PMC9331686 DOI: 10.3390/children9081103
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Epidemiological data and clinical manifestations at admission.
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age in years (months) | 1 (22) | 16 | 3 | 2 | 1 (15) | 0 (8) | 0 (10) | 2 | 17 | 8 |
| Sex | m | m | f | m | m | f | m | m | f | m |
|
| ||||||||||
| Comorbidities | no | no | no | no | no | no | no | no | no | no |
| Immunosuppression | no | no | no | no | no | no | no | no | no | no |
| Trauma | no | no | no | no | no | no | no | yes | yes | yes |
|
| ||||||||||
| Pain | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes |
| Location of pain | hip | spine | hip | spine | legs | legs + hip | abdominal | hip + spine | spine | spine |
| Fever (>38.5 °C) | no | no | no | no | no | no | no | yes | no | no |
| Limping | yes | no | yes | yes | yes | yes | no | yes | no | no |
| Refusal to walk | yes | yes | yes | yes | yes | yes | no | yes | no | no |
| Neurological symptoms | no | no | no | no | no | no | no | no | no | no |
| Time elapsed between clinical onset and establishing the diagnosis (weeks) | 1.5 | 3 | 2.5 | 8 | 3 | 3 | 3 | 1 | 1 | 52 |
| PSD site | L5/S1 | L2/3 | L3/4 | L5/S1 | L5/S1 | L2/3 | L2/3 | L5/S1 | Th10/11 | L4/5 |
|
| ||||||||||
| Paraspinal abscess | yes | no | yes | no | no | yes | no | no | no | no |
| Psoas abscess | no | yes | yes | no | no | yes | no | no | no | yes |
| Destruction of a vertebral body | yes | yes | no | no | no | yes | yes | yes | yes | yes |
m = male; f = female; PSD = pediatric spondylodiscitis.
Laboratory data, microbiological findings, and treatment..
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| ESR (mm/h) | 40 | 44 | 95 | 34 | 125 | 3 | n.a. | n.a. | n.a. | n.a. |
| WBC count (×109/L) | 17.1 | 6.9 | 10.7 | 10.2 | 16.8 | 6.2 | 14.7 | 15.3 | 6 | 7.5 |
| CRP (mg/L) | 4.3 | 48.2 | 9 | 7.6 | 2 | 4.6 | 14.6 | 11.7 | 9.9 | <3 |
| Hb g/dL | 10.5 | 14.5 | 10.2 | 10.9 | 10.7 | 10.2 | 9.5 | 10.4 | 12.4 | 12.9 |
|
| ||||||||||
| Sonography of the hip | yes | no | no | yes | yes | yes | no | yes | no | no |
| X-ray of the extremities /lumbar spine | yes | no | no | no | no | yes | no | yes | no | yes |
| CT | yes | no | no | no | no | no | no | no | yes | no |
| MRI | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes |
|
| ||||||||||
| Number of blood cultures | 2 | 0 | 5 | 2 | 1 | 3 | 3 | 3 | 0 | 2 |
| Blood culture result | sterile | n.a. | sterile | sterile | sterile | sterile | sterile | sterile | n.a. | sterile |
| CT-guided biopsy | yes | yes | no | yes | no | no | no | no | no | yes |
| Open biopsy | no | no | no | no | no | no | no | no | yes | no |
| Tests for tuberculosis | Quantiferon | no | Quantiferon | PCR + culture | Quantiferon | no | Quantiferon | no | no | PCR + culture |
| Biopsy result | sterile |
| sterile | sterile | sterile | sterile | sterile | sterile |
|
|
|
| ||||||||||
| Surgery | no | no | no | no | no | no | no | no | yes | yes |
| Antibiotic i.v. | Cefotaxim Flucloxacillin | Flucloxacillin |
Clindamycin Cefuroxim, Piperacillin/Tazobactam Metronidazol Ciprofloxacin Clindamycin | Clindamycin Cefotaxim | Cefotaxim Flucloxacillin | Cefotaxim | Cefotaxim | Cefotaxim Flucloxacillin | Flucloxacillin | n.a. |
| Antibiotic p.o. | Amoxicillin/Clavulanic acid | no | Ciprofloxacin Clindamycin | no | Amoxicillin/Clavulanic acid | Amoxicillin/Clavulanic acid | n.a. | Amoxicillin/Clavulanic acid | no | Rifampicin Isoniazid Ethambutol Pyrazinamid |
| Total duration of antibiotic therapy (weeks) | 6 | 6 | 6 | 3 | 6 | 6 | min. 2 (Patient was transferred) | 6 | 6 | 21 months |
| Duration of i.v. therapy (weeks) | 3 | 3 | 4 | 3 | 2 | 2 | min. 2 | 2 | 6 | 0 |
| Duration of p.o. therapy (weeks) | 3 | 3 | 2 | 0 | 4 | 4 | n.a. | 4 | 0 | 21 months |
| Duration from admission until initiation of therapy (days) | 16 | 2 | 13 | 1 | 7 | 3 | 6 | 2 | 5 | 2 |
ESR = erythrocyte sedimentation rate (normal value < 20 mm/h); WBC = white blood cell count (normal value is age adapted); CRP = C-reactive protein (normal value < 5 mg/L); Hb = hemoglobin (normal value > 10 g/dL); CT = computed tomography; MRI = magnetic resonance imaging; i.v. = intravenous; p.o. = per os; n.a. = not applicable; n.a, MSSA = Methicillin-Sensitive Staphylococcus aureus; M. tuberculosis = Mycobacterium tuberculosis.
Figure 1X-ray (sagittal view) of the lumbar spine (Pat. No. 10).
Figure 2MRI scan (sagittal view) of the lumbar spine (Pat. No. 10).